Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Bruix J, Sherman M; Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi:10.1002/hep.20933
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2021;2021:1.
   Google Scholar
• Salem R, Johnson GE, Kim E, et al. Yttrium‐90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342–2352. doi:10.1002/hep.31819
   PubMed Web of Science ®Google Scholar
• Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33(4):919–924. doi:10.1016/0360-3016(95)00039-3
   PubMed Web of Science ®Google Scholar
• Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431–438. doi:10.1097/COC.0b013e318168ef65
   PubMed Web of Science ®Google Scholar
• Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc. 2009;70(3):561–567. doi:10.1016/j.gie.2009.03.015
   PubMed Web of Science ®Google Scholar
• Wright CL, Werner JD, Tran JM, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol. 2012;23(5):669–674. doi:10.1016/j.jvir.2012.01.059
   PubMed Web of Science ®Google Scholar
• Narsinh KH, Van Buskirk M, Kennedy AS, et al. Hepatopulmonary shunting: a prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with 90Y radioembolization. Radiology. 2017;282(1):281–288. doi:10.1148/radiol.2016152100
   PubMed Web of Science ®Google Scholar
• Leung WT, Lau WY, Ho SK, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med. 1994;35(1):70–73.
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10(1):12–29. doi:10.1053/j.tvir.2007.08.001
   PubMedGoogle Scholar
• Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–116. doi:10.1007/s00270-011-0142-x
   PubMed Web of Science ®Google Scholar
• Powerski MJ, Scheurig-Munkler C, Banzer J, Schnapauff D, Hamm B, Gebauer B. Clinical practice in radioembolization of hepatic malignancies: a survey among interventional centers in Europe. Eur J Radiol. 2012;81(7):e804–11. doi:10.1016/j.ejrad.2012.04.004
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lago I, Carretero C, Herráiz M, et al. Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. World J Gastroenterol. 2013;19(19):2935–2940. doi:10.3748/wjg.v19.i19.2935
   PubMed Web of Science ®Google Scholar
• Müller SP, Antoch G, Lauenstein T, Amthauer H, Haug AR, Bockisch A. DGN Handlungsempfehlung (S1-Leitlinie): Selektive Intraarterielle Radiotherapie (SIRT) Maligner Lebertumoren. Deutsche Gesellschaft für Nuklearmedizin e.V.; 2014.
   Google Scholar
• Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol. 1997;52(1):36–40. doi:10.1016/S0009-9260(97)80303-0
   PubMed Web of Science ®Google Scholar
• Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol. 2007;18(10):1310–1314. doi:10.1016/j.jvir.2007.07.003
   PubMed Web of Science ®Google Scholar
• Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(Suppl 1):S41–55. doi:10.1148/rg.25si055515
   PubMedGoogle Scholar
• Loke KS, Padhy AK, Ng DC, Goh AS, Divgi C. Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med. 2011;10(2):122–138. doi:10.4103/1450-1147.89780
   PubMedGoogle Scholar
• Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48. doi:10.1148/radiol.2017170554
   PubMed Web of Science ®Google Scholar
• Banerjee S, Wang DS, Kim HJ, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology. 2015;62(3):792–800. doi:10.1002/hep.27877
   PubMed Web of Science ®Google Scholar
• Jang JY, Lee JS, Kim H-J, et al. The general rules for the study of primary liver cancer. J Liver Cancer. 2017;17(1):19–44. doi:10.17998/jlc.17.1.19
   Google Scholar
• Inc S-STSM. Package insert; 2011.
   Google Scholar
• Ho S, Lau W, Leung T, Chan M, Johnson P, Li A. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24(3):293–298. doi:10.1007/BF01728766
   PubMedGoogle Scholar
• Chan Y. Biostatistics 104: correlational analysis. Singapore Med J. 2003;44(12):614–619.
   PubMedGoogle Scholar
• Ziessman HA, Thrall JH, Gyves JW, et al. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983;24(10):871–875.
   PubMed Web of Science ®Google Scholar
• Mei Q, Li Y. Transcatheter arterial embolization of hepatic arteriovenous shunts in patients with hepatocellular carcinoma. Semin Intervent Radiol. 2012;29(3):237–240. doi:10.1055/s-0032-1326935
   PubMedGoogle Scholar
• Gaba RC, Zivin SP, Dikopf MS, et al. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology. 2014;271(2):602–612. doi:10.1148/radiol.14131969
   PubMed Web of Science ®Google Scholar
• Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013;133(9):2165–2171. doi:10.1002/ijc.28230
   PubMed Web of Science ®Google Scholar
• Olorunsola OG, Kohi MP, Behr SC, et al. Imaging predictors of elevated lung shunt fraction in patients being considered for Yttrium-90 radioembolization. J Vasc Interv Radiol. 2015;26(10):1472–1478. doi:10.1016/j.jvir.2015.07.009
   PubMed Web of Science ®Google Scholar
• Yerubandi V, Ronald J, Howard BA, et al. Patient and tumor characteristics predictive of an elevated hepatopulmonary shunt fraction before radioembolization of hepatic tumors. Nucl Med Commun. 2016;37(9):939–946. doi:10.1097/MNM.0000000000000528
   PubMed Web of Science ®Google Scholar
• Kallini JR, Gabr A, Hickey R, et al. Indicators of lung shunt fraction determined by Technetium-99 m macroaggregated albumin in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2017;40(8):1213–1222. doi:10.1007/s00270-017-1619-z
   PubMed Web of Science ®Google Scholar
• Xing M, Lahti S, Kokabi N, Schuster DM, Camacho JC, Kim HS. 90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival. Clin Nucl Med. 2016;41(1):21–27. doi:10.1097/RLU.0000000000000915
   PubMed Web of Science ®Google Scholar
• Powerski MJ, Erxleben C, Scheurig-Münkler C, et al. Hepatopulmonary shunting in patients with primary and secondary liver tumors scheduled for radioembolization. Eur J Radiol. 2015;84(2):201–207. doi:10.1016/j.ejrad.2014.11.004
   PubMed Web of Science ®Google Scholar
• Lüdemann W, Kahn J, Pustelnik D, et al. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol. 2022;2022:1–12. doi:10.1007/s00330-022-08585-x
   Google Scholar
• Deipolyi AR, Iafrate AJ, Zhu AX, Ergul EA, Ganguli S, Oklu R. High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival. J Vasc Interv Radiol. 2014;25(10):1604–1608. doi:10.1016/j.jvir.2014.06.019
   PubMed Web of Science ®Google Scholar
• Schobert I, Chapiro J, Nezami N, et al. Quantitative imaging biomarkers for 90 Y distribution on bremsstrahlung SPECT after resin-based radioembolization. J Nucl Med. 2019;60:1066–1072. doi:10.2967/jnumed.118.219691
   PubMed Web of Science ®Google Scholar
• Ludwig JM, Ambinder EM, Ghodadra A, Xing M, Prajapati HJ, Kim HS. Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis. Cardiovasc Intervent Radiol. 2016;39(7):1007–1014. doi:10.1007/s00270-016-1323-4
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi:10.1016/S1470-2045(17)30683-6
   PubMed Web of Science ®Google Scholar
• Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label Phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi:10.1016/S2468-1253(20)30290-9
   PubMed Web of Science ®Google Scholar
• Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol. 2014;25(2):266–270. doi:10.1016/j.jvir.2013.11.005
   PubMed Web of Science ®Google Scholar
• Gaba RC, Vanmiddlesworth KA. Chemoembolic hepatopulmonary shunt reduction to allow safe yttrium-90 radioembolization lobectomy of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(6):1505–1511. doi:10.1007/s00270-012-0371-7
   PubMed Web of Science ®Google Scholar